Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Parexel Exec Says FDA Keeps Reviews on Track amid Staff Cuts, but Notes Leadership Drain
September 30, 2025
-
COMMENTARY FPMAJ Chair’s Call for Blanket Drug Price Hike: Bold Pitch or Wild Throw?
September 30, 2025
-
BUSINESS Industry Fears Trump’s MFN Drug Pricing Push Could Deepen Japan’s Lag and Loss
September 29, 2025
-
REGULATORY Rift Surfaces over What Constitutes “Objective Review” of CEA
September 29, 2025
-
REGULATORY Panel Flags Concern over Drug-Only Focus in Proposed Cost-Cuts for 2026 Reform
September 29, 2025
-
REGULATORY Pharma Support Needed to Bridge Biotech’s “Valley of Death”: Council Member
September 26, 2025
-
BUSINESS Nippon Zoki Shooting for 50% Overseas Sales by FY2035
September 25, 2025
-
BUSINESS Mochida and Itochu to Each Take 20% Stake in And Pharma
September 24, 2025
-
REGULATORY FPMAJ Calls for Scrapping Huge-Seller, Spillover Re-Pricing at Public-Private WG Hearing
September 24, 2025
-
REGULATORY Japan Approves Pluvicto, Izervay, and Lots More; Subcutaneous Rybrevant Not on Roster
September 22, 2025
-
ORGANIZATION JPMA Sets Up Multilateral Advocacy Group to Bolster Global Voice: International Affairs Chair
September 19, 2025
-
REGULATORY FPMAJ Urges Blanket Drug Price Hikes to Offset Inflation: FY2026 Reform Talks
September 18, 2025
-
REGULATORY J&J’s Subcutaneous Rybrevant Faces Delay in Japan Approval Process
September 17, 2025
-
BUSINESS Alnylam Sees Japan Business Doubling as Amvuttra Expands into ATTR-CM
September 17, 2025
-
BUSINESS Predictability Key to Novartis’ Japan Investment, Says International Chief
September 16, 2025
-
BUSINESS LEO Pharma Reinforces Japan Push toward Dermatology Leadership
September 12, 2025
-
BUSINESS Sawai and T’s Pharma Won Forxiga Generics by Skirting Patent, Will the Strategy Hold?
September 11, 2025
-
REGULATORY Reblozyl Faces Price Cut after Cost-Effectiveness Assessment
September 11, 2025
-
BUSINESS Teijin Pharma Bets on Ascendis Rare Disease Assets as Feburic Sales Crumble
September 10, 2025
-
BUSINESS Amicus CEO Confident on US$1 Billion Sales Target as Japan Pompe Launch Gets Underway
September 9, 2025
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…